Exploring the Utility of [18F]3F4AP for Demyelination Imaging
Status:
RECRUITING
Trial end date:
2030-05-05
Target enrollment:
Participant gender:
Summary
The overall objective is to obtain an assessment of the pharmacokinetics of \[18F\]3F4AP in healthy volunteers and subjects with demyelinating diseases such as mild cognitive impairment (MCI), Alzheimer's Disease (AD), Multiple Sclerosis (MS), Spinal Cord Injury (SCI) and Spinal radiculopathy (SR).
Phase:
PHASE1
Details
Lead Sponsor:
Yale University
Collaborators:
National Institute for Biomedical Imaging and Bioengineering (NIBIB) National Institute on Aging (NIA)